1.
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
2.
3.
4.
5.
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis
datasheet1_Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.docx
Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study
DataSheet1_Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.PDF
6.